Host genomic DNA of autologous CD34+ hematopoietic stem and progenitor cells (CD34+ HSPC genomic DNA)

Host genomic DNA of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) serves as the fundamental substrate for ex vivo gene therapy and genome editing. These multipotent cells are capable of self-renewal and differentiation into all blood lineages, making their genome an ideal target for permanent correction of inherited hematologic and metabolic disorders (Naldini, 2011). In clinical applications, the DNA is modified using lentiviral vectors for gene addition or CRISPR-Cas9 for precise sequence disruption, such as targeting the BCL11A enhancer to treat sickle cell disease (FDA, 2023). By utilizing autologous cells, these therapies eliminate the risk of graft-versus-host disease typically associated with allogeneic stem cell transplants. The therapeutic goal is to achieve stable, long-term expression of the corrected gene within the hematopoietic system. However, the process requires myeloablative conditioning and carries risks of insertional mutagenesis or off-target effects that could potentially lead to secondary malignancies (Hanna et al., 2021).

Other names

Autologous CD34+ HSPC DNAHematopoietic stem cell genomeHSPC genomic DNAAutologous hematopoietic progenitor cell DNA

Modification of the host genome via gene addition (using lentiviral vectors) or gene editing (using CRISPR-Cas9) to restore protein function or alter gene expression patterns.